Hormonal Receptors Evaluation in Breast Cancer

Document Type : Case Report

Authors

1 Assistant Professor, Department of General Surgery, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Resident, Department of General Surgery, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Background: Breast cancer is the most common site-specific cancer in women and is of the major leading causes of death from cancer for women aged 20 to 59 years. This study aimed to demonstrate certain biological, clinical and pathological characteristics and to evaluate the breast receptors of patients with this disease.Methods: In this retrospective and descriptive study, 54 patients with breast cancer were selected to participate. All the cases were treated by modified radical mastectomy (MRM). Data was gathered from patients’ records.Finding: The mean age at which breast cancer was first diagnosed, was 50.23 years (Range: 32-75, SD = 11.00 years) and 86.8% of tumors were invasive ductal carcinoma. The mean tumor size was 4.95 cm (Range: 1-11, SD = 2.64 cm). 39 cases were estrogen receptor positive (72.22%) that 19 of them were in patients with right breast tumor. 12 patients (80%) of 15 cases with negative estrogen receptor, had tumor in right breast. In 33 cases which were progesteron receptor positive, 17 had right breast tumor. 14 patients, of 21 cases with negative progesterone receptor, had tumor in right breast.Conclusion: Most of the patients with negative estrogen or progesterone receptor, had tumors in right breast. So, it may be an important proposition in breast cancer world to discover more about it.

Keywords

References

  1. Guinee VF. Epidemiology of breast cancer. In: Bland KI, Copeland EM, Editors. The breast: comprehensive management of benign and malignant diseases. Philadelphia: W.B. Saunders; 1998. p. 339.
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
  3. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006; 24(33): e49-e50.
  4. Statitics and Information Department Ministers secretariat. Ministry of Health and Welfare: Vital Statistics of Japan in 1997-1999 [Online]. 2002; Available from: URL:
  5. www.soa.org/library/monographs/life/.../mono-2002-m-li-02-1-saito/
  6. Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86(18): 1403-8.
  7. Blackburn GL, Copeland T, Khaodhiar L, Buckley RB. Diet and breast cancer. J Womens Health (Larchmt) 2003; 12(2): 183-92.
  8. Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol 1998; 16(1): 338-47.
  9. Hulka BS. Epidemiologic analysis of breast and gynecologic cancers. Prog Clin Biol Res 1997; 396: 17-29.
  10. Pujol P, Galtier-Dereure F, Bringer J. Obesity and breast cancer risk. Hum Reprod 1997; 12(Suppl 1): 116-25.
  11. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003; 237(4): 474-82.
  12. Wynder EL, Cohen LA, Muscat JE, Winters B, Dwyer JT, Blackburn G. Breast cancer: weighing the evidence for a promoting role of dietary fat. J Natl Cancer Inst 1997; 89(11): 766-75.
  13. Vogel VG. High-risk populations as targets for breast cancer prevention trials. Prev Med 1991; 20(1): 86-100.
  14. Gail MH, Anderson WF, Garcia-Closas M, Sherman ME. Absolute risk models for subtypes of breast cancer. J Natl Cancer Inst 2007; 99(22): 1657-9.
  15. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying) -Linked To County Attributes -Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch released April 2007, based on the November 2006 submission [Online]. 2006 [cited 2008 May 26]; Available from: URL: www.seer.cancer.gov/
  16. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177-82.
  17. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289(24): 3243-53.
  18. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19(4): 980-91.
Journal of Isfahan Medical School
Volume 29, Issue 139 - Serial Number 139
March and April 2011
Pages 621-625

Files

History

  • Receive Date: 21 November 2010
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics